Literature DB >> 20653430

Which allergen extract for grass pollen immunotherapy? An in vitro study.

F Marcucci1, L Sensi, G Di Cara, C Incorvaia, P Puccinelli, S Scurati, F Frati.   

Abstract

BACKGROUND: Grass pollen is a major cause of allergy throughout the world. The only treatment targeting the causes and not only the symptoms of allergy is specific immunotherapy (IT). A number of controlled trials demonstrated the efficacy of IT in grass pollen allergic subjects, most using extracts of multiple grasses but some using extracts of a single grass. The optimal grass extract for IT has not yet been established.
METHODS: This study is aimed at investigating the IgE-binding pattern in sera from IT-naïve patients from central Italy with allergic rhinitis and/or asthma caused by grass pollen. A 5-grass extract was used (containing Dactylis glomerata, Poa pratensis, Lolium perenne, Antoxanthum odoratum and Phleum pratense) and compared to Phleum pratense alone, which is the most frequently used single grass extract, by the RAST-inhibition technique.
RESULTS: The 5-grass extract showed, by RAST-inhibition, a significantly higher binding compared to the Phleum pratense extract for Antoxanthum odoratum and Poa pratensis, while the two extracts for immunotherapy showed similar binding affinity for Phleum pratense and the non-Pooideae grass, Cynodon dactylon.
CONCLUSIONS: The use of a mixed-grass pollen extract seems to be the optimal choice when applying specific IT in grass pollen-allergic subjects from the Mediterranean area.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20653430     DOI: 10.3109/08820131003796876

Source DB:  PubMed          Journal:  Immunol Invest        ISSN: 0882-0139            Impact factor:   3.657


  8 in total

1.  Immunological markers in allergic rhinitis patients treated with date palm immunotherapy.

Authors:  Ghada Boghdadi; Ayman Marei; Atef Ali; Gamal Lotfy; Magdi Abdulfattah; Samir Sorour
Journal:  Inflamm Res       Date:  2012-03-29       Impact factor: 4.575

2.  Economic evaluation of 5-grass pollen tablets versus placebo in the treatment of allergic rhinitis in adults.

Authors:  Matteo Ruggeri; Marco Oradei; Franco Frati; Paola Puccinelli; Cristina Romao; Ilaria Dell'Albani; Cristoforo Incorvaia; Americo Cicchetti
Journal:  Clin Drug Investig       Date:  2013-05       Impact factor: 2.859

3.  Grass-specific CD4(+) T-cells exhibit varying degrees of cross-reactivity, implications for allergen-specific immunotherapy.

Authors:  L D Archila; J H DeLong; E Wambre; E A James; D M Robinson; W W Kwok
Journal:  Clin Exp Allergy       Date:  2014-07       Impact factor: 5.018

4.  5-grass pollen tablets achieve disease control in patients with seasonal allergic rhinitis unresponsive to drugs: a real-life study.

Authors:  Elide Anna Pastorello; Laura Losappio; Stefania Milani; Giuseppina Manzotti; Valentina Fanelli; Valerio Pravettoni; Fabio Agostinis; Alberto Flores D'Arcais; Ilaria Dell'Albani; Paola Puccinelli; Cristoforo Incorvaia; Franco Frati
Journal:  J Asthma Allergy       Date:  2013-12-04

5.  A major step forward for sublingual immunotherapy: the quality of 5-grass pollen tablet is recognized also in Italy.

Authors:  Giorgio Ciprandi
Journal:  J Asthma Allergy       Date:  2015-03-06

6.  A survey on the perception of allergy specialists about the reimbursed grass pollen tablets for seasonal allergic rhinitis in Italy.

Authors:  Ilaria Massaro; Oliviero Rossi; Cristoforo Incorvaia; Carlo Lombardi
Journal:  Clin Mol Allergy       Date:  2017-08-15

7.  T-cell epitope conservation across allergen species is a major determinant of immunogenicity.

Authors:  Luise Westernberg; Véronique Schulten; Jason A Greenbaum; Sara Natali; Victoria Tripple; Denise M McKinney; April Frazier; Heidi Hofer; Michael Wallner; Federica Sallusto; Alessandro Sette; Bjoern Peters
Journal:  J Allergy Clin Immunol       Date:  2016-02-13       Impact factor: 10.793

Review 8.  Multiple grass mixes as opposed to single grasses for allergen immunotherapy in allergic rhinitis.

Authors:  K Gangl; V Niederberger; R Valenta
Journal:  Clin Exp Allergy       Date:  2013-11       Impact factor: 5.018

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.